Economic burden of depressive disorders for people living with HIV in Uganda

Patrick V. Katana,^{1,2*} Ian Ross,^{1,2} Barbra Elsa Kiconco,⁴, Patrick Tenywa,⁴ Melissa Neuman³, Wilber Ssembajjwe⁴, Isaac Sekitoleko⁴, Kenneth Roger Katumba⁴, Eugene Kinyanda⁴, Yoko V. Laurence⁵ and Giulia Greco¹

 ¹ Department of Global Health and Development, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, United Kingdom
 ²Department of Disease Control, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom
 ³Epidemiology and Population Health and MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine
 ⁴ MRC/UVRI & LSHTM Uganda Research Unit
 ⁵ King's College London.

*Corresponding author: patrick.katana@lshtm.ac.uk

Introduction: Between 8–39 % of people living with HIV (PLWH) in sub-Saharan Africa have depressive disorders (DD). Despite considerable gains in the treatment of PLWH, DD is increasingly recognised as a threat to successful treatment and prevention. PLWH are generally known to suffer from stress and incur higher health-related costs compared to the general population due to care management demand throughout their lifespan. There have been limited studies examining healthcare costs borne by PLWH with DD specifically.

Objective: We aimed to estimate the economic burden of DD and HIV amongst PLWH and explore their mechanisms of coping with high out of pocket (OOP) health expenditure.

Methodology: This is a cost of illness study nested in an ongoing cluster-randomised trial assessing the effectiveness of integrating treatment of DD into routine HIV care in Uganda (HIV+D trial). The study is using cross-sectional data collected from 1,115 PLWH at trial baseline, using the Patient Health Questionnaire (PHQ-9) to measure DD and a structured cost questionnaire was administered. Forty public health care facilities that provide HIV care in Kalungu, Masaka and Wakiso Districts were randomly selected, and study participants were recruited amongst their patients. Eligibility criteria were patients attending the HIV clinic, aged \geq 18 years who screen positive for DD (PHQ-9 \geq 10). Economic costs (OOP expenditure and opportunity costs) were estimated from the household perspective.

Results: Mean monthly economic costs amongst those incurring any costs (n=1,115) were NOTK 2555,9010 (USS 68.64). (USS 256.66).

On average, respondents missed 6 days of work per month due to healthcare seeking or illhealth for any condition. Key cost drivers were facility bed charges and medication. The majority of respondents (73%) borrowed money from families and friends to cope with the economic burden. About 29.7% reported moderate (PHQ-9 15-19) and 5.12% severe (PHQ- $9 \ge 20$) DD symptoms. Respondents with moderate or severe DD had slightly higher average monthly costs than those with mild DD (PHQ-10-14), but the difference was not statistically significant.

Conclusion: People living with HIV who experience DD incur in high OOP expenditure and productivity losses. The monthly OOP health expenditure is in the range of 23% of their monthly household income. Social protection mechanisms combined with the integration of the management of DD into routine HIV care could alleviate this burden.

keywords: HIV/AIDS, depression, economic burden, PHQ-9

Background

Globally, approximately 38.4 million people are living with HIV (PLWH) and of these, between 8-39% have depressive disorders (DD) (Kinyanda et al. 2011b; Kinyanda et al. 2017; Myer et al. 2008; Kinyanda et al. 2021). In Uganda, 31% of the estimated 1.4 million PLWH continue to suffer from depression according to a recent meta-analysis (Wagner, Slaughter, and Ghosh-Dastidar 2017). Despite the tremendous progress made to improve access to HIV care in the region, DD remains a significant threat to the fight against HIV, because DD may impact on HIV treatment adherence and risky sexual behaviour. Several studies have shown PLWH suffer from stress and incur higher health-related costs compared to the general population due to care management demands throughout their lifespan (Kinyanda et al. 2011a; Abas et al. 2014; Uthman et al. 2014).

The increased life expectancy for PLWH and DD due to improvements in treatment and care comes with the responsibility of lifelong caring, the cumulative costs for which are substantial (Cohen et al. 2020; Gandhi et al. 2023). This requires patients and family members to bear costs which PLWH and their families are most times not able to bear on their own. These costs can include direct expenses such as medical consultations and drugs (Kirch 2008) or indirect expenses such as reduced productivity (Boccuzzi 2003). Sometimes it can push a family into poverty.

Although antiretroviral therapy (ART) drugs for HIV/AIDS are free of charge for patients at public health centres in Uganda and many parts of the world, patients can still incur costs for comorbid conditions (Pinto et al. 2013). In particular, DD can increase the costs of HIV care through increased visits to health facilities when compared with PLWH without DD (Kinyanda et al. 2017). Most PLWH still incur medical costs (medicine, consultation) to treat opportunistic infections in addition to non-medical costs such as transport and food (Pinto et al. 2013). Furthermore the costs may be catastrophic to people in fragile economic situations in the context of low insurance coverage (Barennes et al. 2015).

To meet the costs of illness, patients and caregivers of PLWH may adopt coping strategies such as the sale of assets or borrowing from relatives or a lending institution (Sauerborn, Adams, and Hien 1996; Russell 1996; McIntyre et al. 2006). Such strategies can help to cope with immediate economic burden; however, they can also be potentially 'risky' for their future financial wellbeing. The selling of livelihood assets, for instance, reduces the caregiver's or family's ability to generate future income (Flores et al. 2008).

Although several studies have focused on the economic burden of HIV on patients' wellbeing, quality of life and mental health (Maheswaran et al. 2018; Jakubowski et al. 2022; Katana et al. 2020) no studies have been found that evaluate caregivers' economic burden and its association with severity of DD. It is against this background that a cost of illness assessment within a cluster-randomised trial of integrated management of depression into routine HIV care (HIV+D) was undertaken. Using the patient cost data collected at baseline this study sought to estimate the economic burden of depressive disorders among PLWH in Uganda. We assessed both direct and indirect costs of illness incurred by PLWH and DD. We also elicited coping startegies employed to meet the economic demands of care and treatment. Finally, we assessed the severity of depressive symptoms that may be associated with meeting the demands of care and treatment for patients living with HIV and DD.

Method

Study setting

Uganda is a low-income country with a population of 45 million people and a gross national income per capita of US\$884 for the yaer 2021 ((World Bank; Wagner, Slaughter, and Ghosh-Dastidar 2017). It is estimated that 30% of this population lives below the poverty line of USD 1.77 per person each day (UBOS 2021). A strong association between depression and poverty has been shown, and PLWH are at a much higher risk (Cleary et al. 2020; Rutakumwa et al. 2023). In addition, 9.8% of Uganda's gross domestic product (GDP) is spent on healthcare but only 1% of this total health expenditure is allocated to mental health (Molodynski, Cusack, and Nixon 2017). Despite access to free HIV care at point of delivery, PLWH spend close to 10% of their household income seeking health care and are at a risk of being pushed further into poverty because of catastrophic health expenditure (Chuma, Gilson, and Molyneux 2007; Kakaire et al. 2016)

The HIV+D trial was carried out in 40 public health facilities (PHFs) that provide HIV care in semi-urban and rural settings of central Uganda. The central region in Uganda has the second highest prevalence rate of HIV nationally, estimated at 7.6% (Ssebunnya et al. 2021). The HIV+D study was a cluster-randomised trial (Kinyanda et al. 2021) that examined effectiveness and cost-effectiveness of integrating the management of depression into routine HIV Care. A minimum of 10 and a maximum of 30 eligible participants were recruited from each of the 40 PHFs in the districts of Kalungu, Masaka and Wakiso. PLWH who were 18 years and above and were on ART for at least 6 months were recruited through random sampling from HIV care clinics.

Study design

This was a cross-sectional study nested into the HIV+D trial. Cost data was collected from patients at baseline, 3 months, and 12 months through face-to-face interviews at the PHFs between May 2021 and December 2022. For this study, we used baseline data from the study population of 1,115 PLWH and DD across both trial arms.

Ethics

Ethical approval to conduct this study was obtained from Uganda National Council for Science and Technology (reference number HS645ES), the Uganda Virus Research Institute (UVRI) Research and Ethics Committee (reference number GC/127/20/04/772), and the London School of Hygiene and Tropical Medicine (LSHTM) Ethics Committee (reference number 22,567) (Kinyanda et al. 2021). Informed consent was obtained from all individuals participating in the study.

Data Collection

We developed a questionnaire that was used to retrospectively collect patient incurred cost data at the baseline of the HIV+D study from May 2021 to December 2022. The patient cost questionnaire was translated from English to Luganda (the predominantly used local language) and then back translated to ensure accuracy and coherence by the HIV+D Health Economics team in consultation with social scientists that were not part of the HIV+D study and a phsychologist who was a member of the HIV+D study team. Both the latter and the former

were experienced with translation of research questionnaires. This baseline patient cost questionnaire tool contained questions on direct and indirect costs, coping strategies, visit type (outpatient and inpatient), household income, household expenditure and sociodemographic information, with specific reference to the previous month only so as to minimise recall bias. A paper questionnaire was administered through face-to-face interviews lasting 30-40 minutes. Completed questionnaires were reviewed by the research team for missing information, then data was entered into the study database in OpenClinica for cleaning and analysis.

Data analysis

We applied a cost of illness approach and included direct and indirect costs.

Direct costs were measured by combining the average costs per patient for out of pocket (OOP) medical and non-medical expenditure for inpatient and outpatient visits. These included adminidtrative costs e.g consultation fees for clinicians, daily hospital charges, user fees at HCFs, HIV and DD diagnostic test fees, the cost of HIV and DD drugs, supplementary foods, and return travel to HCFs for diagnostic and treatment visits. In addition to regular visits to the HIV clinics, some PLWH also visited the HCF for separate depression treatment. In our study, the costs attributable to both HIV and depression visits were combined.

Indirect costs were estimated by capturing the loss of productive working time and calculating wages using the human capital approach. Productivity losses by patients and caregivers or accompanying persons (as reported by patients) was estimated by multiplying the number of days lost due to DD (which included time for seeking or receiving care or periods of inability to work) by a value for time. We assumed an average adult will work for 8 hours in a day, so a day's wage lost is equivalent to 480 minutes. To apply a common denominator, all income (in cash or in kind) was converted to a daily rate by using the assumptions of 5 working days in a week on average, 20 in a month, and 260 in a year. If the patient earned a wage, their time was valued using the average of their reported income over the past month from the primary job divided by 20 days. If they had secondary job(s), then we summed the reported income across all jobs to obtain the total daily wage of the person over the past month. Average productivity costs were calculated by multiplying that daily wage by the number of days lost as a result of seeking and receiving HIV and depression care.

The average cost of HIV and DD care was computed as the sum of direct and indirect costs over the duration of one month. Our primary result is the average cost where the denominator includes individuals who reported at least one non-zero cost item (i.e. average cost amongst those incurring costs). We also report the average cost where the denominator is the whole sample (i.e. average cost in the study population include zero or missing values). Missing values were interpreted as zero costs. Costs were collected in Uganda shillings and converted to United States Dollars (US\$) for analysis at the average exchange rate for 2022 of 0.003 (currencyconveter)

Coping strategies

Respondents were asked about coping strategies (e.g. borrowing, use of savings, selling household assests), the source of any borrowed resources (e.g. from friends, a bank, or other sources) and any interest charged on loans.

Depressive disorders (DD)

The 9-item Patient Health Questionnaire (PHQ-9) (Kaggwa et al. 2022) was administered to screen for eligibility in the trial at baseline. The PHQ-9 provides an indicator of depressive severity, with items scored on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day). Total scores are a sum of item scores, so range from 0 to 27 (worst possible). As a measure of severity, PHQ-9 scores are interpreted as 0-4 (minimal DD), 5-9 (minor), 10-14 (mild), 15-19 (moderate) and 20> (severe). In this study, we used a cut-off \geq 10 for eligibility, which maximised sensitivity and specificity in a study conducted in Uganda (Akena et al. 2013). To assess the association between cost and PHQ-9 score, we divide the PHQ-9 score into two groups: mild (10-14) and moderate/severe (>=15).

Analysis

We used descriptive statistics to summarise all socio-demographic, visit type, coping strategies and depressive symptoms variables. Means and medians of continuous data and proportions for categorical data were summarised. We used principal component analysis (PCA) of asset ownership variables to generate a wealth index and quintiles for the whole household sample (Vyas and Kumaranayake 2006). Since the cost data were highly skewed, we used a generalised linear regression model with gamma family and log link to assess the association between cost and PHQ-9 score and accounted for clustering by clinic. Gamma distributions are commonly used to analyse skewed cost data (Veazie et al. 2023). We considered alternative specifications and considered the Bayesian Information Criterion and distribution of residuals to inform model selection.

Results

A total of 1,118 people living with HIV and depression symptoms were approached to participate in this sub-study. Three were excluded because they were below 18 years old. Consequently, analysis involved 1,115 respondents who completed the structured patient cost questionnaire. Most of the participants were female (77.0%) and from Wakiso district (Table 1). The mean age of participants was 39 years (SD=12.02) and about 39.3% had no formal education. About a half (48%) were married or living with someone and the majority were Christians (85.6%). The mean PHQ-9 score was 13.7 (SD=3.14). About a fifth applied coping strategies to cope with depression and HIV care management.

Table 1. Baseline characteristics of study population

	By gender (1,115, %)		By PHQ-9 sc	ore (1,115, %)
	Female	Male	PHQ-9 10-14	PHQ-9 ≥ 15
Characteristic (n= 1,115)	859 (77.0)	256 (23.0)	728 (65.3)	387 (34.7)
Age (years)				
18-25	120 (14.2)	20 (7.9)	88 (12.3)	52 (13.6)
26-35	311 (36.8)	53 (20.9)	237 (33.1)	127 (33.2)
36-45	230 (27.2)	85 (33.6)	200 (27.9)	115 (30.1)
46-55	121 (14.3)	66 (26.1)	125 (17.4)	62 (16.2)
56+	64 (7.6)	29 (11.5)	67 (9.3)	26 (6.8)
Educational attainment				
No formal education	349 (40.6)	89 (34.8)	283 (38.9)	155 (40.1)
Primary	371 (43.2)	109 (42.6)	324 (44.5)	156 (40.3)
Secondary	118 (13.7)	49 (19.1)	104 (14.3)	63 (16.3)
Tertiary education	21 (2.4)	9 (3.5)	17 (2.3)	13 (3.4)
Employment status				

Engaged in an income generating activity in past month	124 (14.6)	29 (11.5)	95 (13.2)	58 (15.1)
Not engaged in an income generating activity	724 (85.4)	224 (88.5)	623 (86.8)	325 (84.9)
Marital status				
Single	85 (9.9)	39 (15.2)	72 (9.9)	52 (13.4)
Married	391 (45.5)	145 (56.6)	346 (47.5)	190 (49.1)
Widowed	122 (14.2)	12 (4.7)	101 (13.9)	33 (8.5)
Separated or divorced	261 (30.4)	60 (23.4)	209 (28.7)	112 (28.9)
Religion				
Catholic	392 (45.6)	141 (55.1)	352 (48.4)	181 (46.8)
Protestant	328 (38.2)	328 (38.2)	328 (38.2)	153 (39.5)
Muslim	139 (16.2)	25 (9.8)	111 (15.2)	53 (13.7)
PHQ-9 score (mean/SD)				
mean	13.57	14.15	11.86	17.18
(Median, SD)	(13, 3.06)	(14, 3.37)	(12, 1.49)	(16, 2.39)
Used coping strategies				
Yes	176 (20.5)	40 (15.7)	136 (18.7)	80 (20.8)
No	682 (79.5)	214 (84.3)	591 (81.3)	305 (79.2)
Socio-economic status				
Poor	153 (17.9)	68 (27.2)	143 (19.9)	78 (20.3)
poorer	181 (21.2)	44 (17.6)	151 (21.0)	74 (19.2)
Middle	177 (20.8)	52 (20.8)	147 (20.5)	82 (21.3)
Richer	162 (19.0)	46 (18.4)	140 (19.5)	68 (17.7)
Richest	180 (21.1)	40 (16.0)	137 (19.1)	83 (21.6)
District				
Kalungu	143 (16.6)	37 (14.5)	128 (17.6)	52 (13.4)
Masaka	187 (21.8)	75 (29.3)	172 (23.6)	90 (23.3)
Wakiso	529 (61.6)	144 (56.2)	428 (58.8)	245 (63.3)

Please include footnotes for all tables where you define the acronyms. Including PHQ-9

Economic costs

The mean economic cost of illness where the denominator is the number of individuals reporting at least one non-zero cost (n=1,115) was UGX 255,910 (US\$ 68.64) per month. The median was UGX 109,702 (US\$ 29.43) per month with inter-quartile range UGX 53,000 (US\$ 14.22) to UGX 256500 (US\$ 68.80). Direct cost constituted 59% of the average total cost. The key drivers of direct costs were daily bed hospital charges for inpatients and HIV medication. The mean economic cost of illness where the denominator was the whole sample (n=1115) was UGX 18840 (US\$ 5.05) per month. The median was UGX 0 (US\$ 0.00) with inter-quartile range [0- 1.61].

Table 2 Economic cost to patients with HIV a	ind depression
--	----------------

N(observation) reporting non-ze cost per item		Mean monthly c amongst those rep cost for tl	Median USD [IQR]	
Direct Costs		UGX (SD)	USD (SD)	
Direct Medical costs				
Daily bed charges	28	102,929 (200,022)	27.27 (52.99)	10.60 [5.56-39.74]
Consultation fees	24	14,208 (11,209)	3.76 (2.97)	2.65 [1.32-5.30]

User fees	21	22,214 (24,323)	5.89 (6.45)	2.65 [1.86-7.95]
Laboratory fees	25	16,400 (11,662)	4.35(3.09)	5.30 [1.33-5.30]
Radiology fees	6	40,000 (30,332)	10.60 (8.04)	7.95 [5.30-10.60]
Other procedures	13	16,039 (18,054)	4.25 (4.79)	2.65 [1.33-5.30]
HIV drugs	12	40,667 (11,3356)	10.78 (30.05)	1.46 [1.19-4.64]
Depression drugs	34	26,132 (39,094)	6.98 (10.45)	4.01 [1.87-6.68]
Other drugs	33	118,79 (11,238)	3.18 (3.00)	1.60 [1.34-4.01]
Supplements	22	27,818 (46,347)	7.44 (12.39)	2.67 [2.14-4.81]
Other medical costs	30	22,733 (31,321)	6.08 (8.37)	2.87 [1.87-8.02]
Direct Non-Medical costs				
Travel	455	8,458 (10,691)	2.26 (2.86)	1.60 [1.07-2.67]
food	37	17,446 (29,424)	4.66 (7.86)	1.34 [0.80-5.35]
Other non-medical costs	36	19,311 (36,427)	5.16 (9.74)	1.20 [0.29-5.35]
Indirect Costs				
Informal productivity loss &	78	105,216 (472,308)	28.22 (126.69)	2.95 [0.52- 9.39]
wages				

The average number of days lost was 6 days per month, and average productivity loss due to HIV and depression were UGX 105,216 (US\$ 28.22) per month (Table 2).

The mean out-of-pocket costs was UGX 94,500 (US\$ 25.60) per month for the non-zero costs, or about 14.5% of estimated average monthly income of households UGX 652,200 (US\$ 174.94), and the median was UGX 33,500 (US\$ 8.78), or 5.1% of median monthly income. The average indirect cost respresents about 41% of the total cost. Mean total costs were considerably higher than medians, due to outliers with much higher indirect costs.

Patient cost and depressive disorder

A total of 726 (65.2%), 330 (29.7%) and 57 (5.12%) of patients had mild, moderate and severe depressive symptoms respectively. Table 3 compares costs for those with moderate/severe depression (34.8%) to those with mild symptoms. The aggregate of both direct and indirect cost for PLWH and depression were higher among those with a moderate and severe compared to those with minor and mild. The mean economic cost of illness amongst individuals reporting non-zero costs was UGX 244,679 (US\$ 65.59) per month for people with mild depressive symptoms, compared to 257,474 (US\$ 69.02) per month for moderate and severe. However, this difference was not statistically significant (p=0.25).

Cost categories	Mild depressive symptoms (PHQ score 10-14)			Moderate & Severe depressive symptoms (PHQ score ≥15)			
	N(obser vation)	Mean costs. (SD)	Median costs [IQR]	N(obs ervati on)	Mean costs [IQR]	Median costs [IQR]	p-value*
Direct Costs							
Direct Medical							
costs							
Daily charges	20	18.19 (28.63)	10.69 (11.76)	8	50.82 (89.05)	21.38 (34.75)	0.107
Consultation fees	13	3.47 (2.09)	2.67 (4.01)	11	4.18 (3.89)	2.67 (4.01)	0.572
User fees	14	6.62 (7.70)	3.74 (8.02)	7	4.58 (3.05)	2.67 (5.88)	0.224
Laboratory fees	15	3.74 (2.47)	2.67 (4.01)	10	5.35 (3.83)	5.35 (5.35)	0.203
Radiology fees	4	12.70 (9.61)	9.36 (12.03)	2	6.68 (1.89)	6.68 (2.67)	0.133
Other procedures	9	5.00 (5.62)	2.67 (4.01)	4	2.67 (2.00)	2.41 (2.67)	0.155
HIV drugs	8	2.17 (2.02)	1.34 (2.27)	4	28.27 (52.45)	2.81 (54.39)	0.000

Table 3 Patients costs in USD per month and depression outcomes

		1	I		1		
Depression drugs	22	6.88 (7.63)	4.68 (5.35)	12	7.17 (14.71)	3.34 (3.61)	0.945
Other drugs	21	2.88 (2.43)	1.60 (2.67)	12	3.70 (3.88)	2.14 (4.41)	0.441
Supplements	15	7.77 (13.45)	2.67 (3.21)	7	6.72 (10.68)	2.67 (3.47)	0.813
Other medical	20	5.21 (6.41)	2.67 (5.21)	10	7.80 (11.58)	3.88 (5.35)	0.464
costs							
Direct Non-							
Medical costs							
Travel	300	2.20 (2.10)	1.60 (1.60)	155	2.38 (3.94)	1.60 (1.60)	0.628
food	29	5.42 (8.72)	2.41 (4.81)	8	1.90 (1.77)	1.20 (1.87)	0.035
Other non-	27	4.13 (8.01)	1.07 (5.08)	9	8.27 (13.84)	1.34 (4.81)	0.291
medical costs							
Indirect Costs							
Informal	47	16.73 (60.50	2.01 (11.57)	31	35.80	3.35 (8.68)	0.396
productivity loss					(155.98)		
& wages							

USD United States Dollars, SD Standard deviation, IQR Interquartile range

Coping strategy

Overall, 19% of study participants employed one or more coping strategy (figure 1), the majority (73%) of whom borrowed from family and friends, followed by other sources and least from banks. We observed higher payback amount than the amount borrowed in most participants and majority were yet to complete servicing their borowed amount.



Figure 1 Coping Strategies

Discussion

This study examined the economic burden of DD for PLWH, using data from 1,115 participants. The majority of our participants were female (77%), which is likely to reflect the higher rates of DD amongst female PLWH in Uganda (Waldron et al. 2021). We observed that patients with moderate and mild depression symptoms had a slightly higher (not statistically significant) economic burden on average compared to those with minor and mild. Amongst those incurring non-zero costs the economic burden was high, representing nearly a quarter of the average monthly household income.

This economic burden is likely to affect individual and household wellbeing (Hughes, Giobbie-Hurder et al. 1999, Lopez-Bastida, Oliva-Moreno et al. 2009, Opoku-Boateng, Kretchy et al. 2017) as financial resources for other basic needs and investments are being diverted to pay for out of pocket health expenditure, and it may result in catastrophic health expenses in the context of fragile economic balance and low insurance coverage (Barennes et al. 2015; Katumba et al. 2023)

The high burden was associated with daily charges for hospitalisation and productivity loss. These results have a two-fold implication on policy planning for health care. First, We hypothesize that the hospitalisation might have resulted from opportunistic diseases hence the need for antiretroviral therapy adherence-enhancing interventions to reduce vulnerability to opportunistic infections (Holmes et al. 2006; Pinto et al. 2013; Katumba et al. 2023). Secondly, productivity loss is an important component often overlooked. Surprisingly few studies have investigated productivity loss in the context of HIV in sub-Saharan Africa. A study in Kenya (Katana et al. 2020) reported lower but comparable productivity costs than our findings. Higher productivity costs might be due to the following reasons: i) HIV and depression care

management clinics are located far from the care recipients, ii) poverty among the households which hinders accessibility to healthcare services hence, iii) productivity losses were valued using the average daily reported wage multiplied by the number of days lost while other studies have applied the human capital approach to presentism and absenteeism vi) worse treatment outcomes among the care recipients hence leading to loss of productive time for the patient and the caregiver, and vii) non-zero costs were reported compared to other studies which include zeros for most HIV comprehensive care services.

Patients living with HIV and depression in this setting applied various coping strategies to meet their care needs. We observed that most patients preferred borrowing from friends and relatives. Perhaps this can be explained by the favourable credit terms from friends and family members, unlike banks and other financial institutions, which require collateral and highinterest rates. Some participants borrowed from banks, where they risked losing family assets if they were unable to make payments on time.

Nearly 35% of the patients screened positive for moderate or severe depressive symptoms. Even though not statistically significant, high direct and indirect costs were observed in patients with moderate and severe depressive symptoms. A similar trend was observed in studies by (Katana et al. 2020) and (Harmanci and Cetinkaya Duman 2016).

The study has some limitations; first, the results may be subjected to recall bias by the respondents. Including limiting the recall period to 1 month, and what could have been done, to limit recall bias. Second, we have missing data and zeros, which were excluded from the analysis; as a consequence, these costs may be imprecisely estimated.

Since our study took place at the time of the Covid pandemic there might have been an underestimation of the cost considering the movement restriction during that period; results may to some extent, be generalizable in similar districts in Uganda. Qualitative study on the economic burden of PLWH and depression may help complement our findings. We recommend financial protection/coverage for OOP payments provided for HIV care should be broadened to capture key diseases that are comorbid with HIV (such as DD and TB) so that the outcomes are not worsened. It would also be important to support local community services for DD so that these can be more accessible, particularly for disenfranchised populations.

Conclusion

The economic burden arising from care and management of HIV and depression remains high and of significant public health concern. Although ARVs are highly subsidized in most HIV clinics in Uganda, patients still incur considerable expenses relative to their incomes. This high economic burden may potentially contribute to depressive symptoms and poor mental health functioning on top of a vicious cycle of poverty. Social programmes to support individuals and families living with HIV is highly recommended.

Declarations

Ethics approval and consent to participate

Ethical approval to conduct this was obtained from the Uganda Virus Research Institute (UVRI) Research and Ethics Committee (reference number GC/127/20/04/772), the Uganda National Council for Science and Technology (reference number HS645ES), and the London

School of Hygiene and Tropical Medicine (LSHTM) Ethics Committee (reference number 22567). All methods were performed in accordance with relevant local and interntional guidelines and regulations (e.g Declaration of Helsinki). Informed consent was documented in writing for each participant prior to the administration of the questionnaire.

Consent for publication

Not Applicable

Availability of data and materials

The datasets used and/or anlysed in this article are available from the corresponding author on request; we will publish the data and analysis codes on OSF.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was funded by Wellcome Trust

Author's Contributions

YVL, GG & EK conceptualized of the study. YVL, GG designed the study. YVL, GG designed and developed study tools. YVL, GG, PT, WS, BEK, EK & KRK contributed to data collection. PVK, IR ,GG & YVL contributed to data analysis. PVK ,YVL, GG, MN, & IR contributed to the interpretation of the data. PVK wrote the first draft of the manuscript. YVL, GG, MN, KRK, BEK, PT, IS & IR critically reviewed the manuscript. All authors have read and approved the submitted manuscript.

Acknowledgements

The authors wish to thank all participants who took part in the study

Authors information

Affiliations and Authors

Department of Global Health and Development, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, United Kingdom Patrick V. Katana, Ian Ross & Giulia Greco

Department of Disease Control, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom

Patrick V. Katana & Ian Ross

Epidemiology and Population Health and MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine

Melissa Neuman

MRC/UVRI & LSHTM Uganda Research Unit

Barbra Elsa Kiconco, Patrick Tenywa, Wilber Ssembajjwe , Isaac Sekitoleko, Kenneth Roger Katumba & Eugene Kinyanda

King's College London Yoko V. Laurence

References

- Abas, Melanie, Gemma-Claire Ali, Etheldra Nakimuli-Mpungu, and Dixon Chibanda. 2014. "Depression in people living with HIV in sub-Saharan Africa: time to act." In, 1392-96.
- Akena, Dickens, John Joska, Ekwaro A Obuku, and Dan J Stein. 2013. 'Sensitivity and specificity of clinician administered screening instruments in detecting depression among HIV-positive individuals in Uganda', *AIDS care*, 25: 1245-52.
- Barennes, Hubert, Amphonexay Frichittavong, Marissa Gripenberg, and Paulin Koffi. 2015. 'Evidence of high out of pocket spending for HIV care leading to catastrophic expenditure for affected patients in Lao People's Democratic Republic', *PLoS ONE*, 10: e0136664.
- Chuma, Jane, Lucy Gilson, and Catherine Molyneux. 2007. 'Treatment-seeking behaviour, cost burdens and coping strategies among rural and urban households in Coastal Kenya: an equity analysis', *Tropical Medicine & International Health*, 12: 673-86.
- Cleary, S., S. Orangi, E. Garman, H. Tabani, M. Schneider, and C. Lund. 2020. 'Economic burden of maternal depression among women with a low income in Cape Town, South Africa', *BJPsych Open*, 6: e36.
- Cohen, Joshua P, Anne Beaubrun, Yao Ding, Rolin L Wade, and Dionne M Hines. 2020. 'Estimation of the incremental cumulative cost of HIV compared with a non-HIV population', *PharmacoEconomics-Open*, 4: 687-96.
- currencyconveter.

'https://www.xe.com/currencyconverter/convert/?Amount=1&From=UGX&To=USD'

- Flores, Gabriela, Jaya Krishnakumar, Owen O'Donnell, and Eddy Van Doorslaer. 2008. 'Coping with health-care costs: implications for the measurement of catastrophic expenditures and poverty', *Health economics*, 17: 1393-412.
- Gandhi, Aditya R, Emily P Hyle, Justine A Scott, Jasper S Lee, Fatma M Shebl, John A Joska, Lena S Andersen, Conall O'Cleirigh, Steven A Safren, and Kenneth A Freedberg. 2023.
 'The clinical impact and cost-effectiveness of clinic-based cognitive behavioral therapy for people with HIV, depression, and virologic failure in South Africa', *Journal of acquired immune deficiency syndromes (1999)*, 93: 333.
- Harmanci, Pinar, and Zekiye Cetinkaya Duman. 2016. 'Investigating relationship between burden of caregivers of patients with schizophrenia and mental health conditions', Journal of Psychiatric Nursing, 7.
- Holmes, Charles B, Robin Wood, Motasim Badri, Sophia Zilber, Bingxia Wang, Gary Maartens, Hui Zheng, Zhigang Lu, Kenneth A Freedberg, and Elena Losina. 2006. 'CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment', JAIDS Journal of Acquired Immune Deficiency Syndromes, 42: 464-69.

- Jakubowski, Aleksandra, Jane Kabami, Laura B Balzer, James Ayieko, Edwin D Charlebois, Asiphas Owaraganise, Carina Marquez, Tamara D Clark, Douglas Black, and Starley B Shade. 2022. 'Effect of universal HIV testing and treatment on socioeconomic wellbeing in rural Kenya and Uganda: a cluster-randomised controlled trial', *The Lancet Global Health*, 10: e96-e104.
- Kaggwa, Mark Mohan, Sarah Maria Najjuka, Scholastic Ashaba, and Mohammed A Mamun.
 2022. 'Psychometrics of the Patient Health Questionnaire (PHQ-9) in Uganda: a systematic review', Frontiers in Psychiatry, 13: 781095.
- Kakaire, Tom, Walter Schlech, Alex Coutinho, Richard Brough, and Rosalind Parkes-Ratanshi.
 2016. 'The future of financing for HIV services in Uganda and the wider sub-Saharan Africa region: should we ask patients to contribute to the cost of their care?', BMC public health, 16: 1-5.
- Katana, Patrick V, Amina Abubakar, Moses K Nyongesa, Derrick Ssewanyana, Paul Mwangi, Charles R Newton, and Julie Jemutai. 2020. 'Economic burden and mental health of primary caregivers of perinatally HIV infected adolescents from Kilifi, Kenya', *BMC Public Health*, 20: 1-9.
- Katumba, Kenneth R, Cally J Tann, Emily L Webb, Patrick Tenywa, Margaret Nampijja, Janet Seeley, and Giulia Greco. 2023. 'The economic burden incurred by families caring for a young child with developmental disability in Uganda', *PLOS Global Public Health*, 3: e0000953.
- Kinyanda, E., S. Hoskins, J. Nakku, S. Nawaz, and V. Patel. 2011a. 'Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda', *BMC Psychiatry*, 11.
- Kinyanda, Eugene, Susan Hoskins, Juliet Nakku, Saira Nawaz, and Vikram Patel. 2011b. 'Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semiurban Entebbe district, Uganda', *BMC psychiatry*, 11: 1-9.
- Kinyanda, Eugene, Leticia Kyohangirwe, Richard S Mpango, Christine Tusiime, Joshua Ssebunnya, Kenneth Katumba, Patrick Tenywa, James Mugisha, Geoffrey Taasi, and Hafsa Sentongo. 2021. 'Effectiveness and cost-effectiveness of integrating the management of depression into routine HIV Care in Uganda (the HIV+ D trial): A protocol for a cluster-randomised trial', *International journal of mental health systems*, 15: 1-11.
- Kinyanda, Eugene, Noeline Nakasujja, Jonathan Levin, Harriet Birabwa, Richard Mpango, Heiner Grosskurth, Soraya Seedat, and Vikram Patel. 2017. 'Major depressive disorder and suicidality in early HIV infection and its association with risk factors and negative outcomes as seen in semi-urban and rural Uganda', *Journal of affective disorders*, 212: 117-27.
- Maheswaran, Hendramoorthy, Stavros Petrou, Danielle Cohen, Peter MacPherson, Felistas Kumwenda, David G Lalloo, Elizabeth L Corbett, and Aileen Clarke. 2018. 'Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: A prospective hospital cohort study in Malawi', *PLoS ONE*, 13: e0192991.
- McIntyre, Diane, Michael Thiede, Göran Dahlgren, and Margaret Whitehead. 2006. 'What are the economic consequences for households of illness and of paying for health care in low-and middle-income country contexts?', *Social science & medicine*, 62: 858-65.
- Molodynski, Andrew, Christina Cusack, and Jurua Nixon. 2017. 'Mental healthcare in Uganda: desperate challenges but real opportunities', *BJPsych international*, 14: 98-100.

- Myer, Landon, Joalida Smit, Liezel Le Roux, Siraaj Parker, Dan J Stein, and Soraya Seedat. 2008. 'Common mental disorders among HIV-infected individuals in South Africa: prevalence, predictors, and validation of brief psychiatric rating scales', AIDS patient care and STDs, 22: 147-58.
- Pinto, Andrew D, Monique van Lettow, Beth Rachlis, Adrienne K Chan, and Sumeet K Sodhi. 2013. 'Patient costs associated with accessing HIV/AIDS care in Malawi', *Journal of the International AIDS Society*, 16: 18055.
- Russell, Steven. 1996. 'Ability to pay for health care: concepts and evidence', *Health policy and planning*, 11: 219-37.
- Rutakumwa, Rwamahe, Christine Tusiime, Richard Stephen Mpango, Leticia Kyohangirwe, Pontiano Kaleebu, Vikram Patel, and Eugene Kinyanda. 2023. 'A Qualitative Exploration of Causes of Depression among Persons Living with HIV Receiving Antiretroviral Therapy in Uganda: Implications for Policy', *Psychiatry Journal*, 2023.
- Sauerborn, Rainer, Alayne Adams, and Maurice Hien. 1996. 'Household strategies to cope with the economic costs of illness', *Social science & medicine*, 43: 291-301.
- Ssebunnya, Joshua, James Mugisha, Richard Mpango, Leticia Kyohangirwe, Geofrey Taasi, Hafsa Ssentongo, Pontiano Kaleebu, Vikram Patel, and Eugene Kinyanda. 2021. 'Using Theory of Change to inform the design of the HIV+ D intervention for integrating the management of depression in routine HIV care in Uganda', *PLoS ONE*, 16: e0259425.
- UBOS. 2021. 'UGANDA NATIONAL HOUSEHOLD SURVEY 2019/2020 REPORT'. https://www.ubos.org/wp-content/uploads/publications/09_2021Uganda-National-Survey-Report-2019-2020.pdf.
- Uthman, Olalekan A, Jessica F Magidson, Steven A Safren, and Jean B Nachega. 2014. 'Depression and adherence to antiretroviral therapy in low-, middle-and high-income countries: a systematic review and meta-analysis', *Current Hiv/aids Reports*, 11: 291-307.
- Veazie, Peter, Orna Intrator, Bruce Kinosian, and Ciaran S Phibbs. 2023. 'Better performance for right-skewed data using an alternative gamma model', *BMC Medical Research Methodology*, 23: 298.
- Vyas, Seema, and Lilani Kumaranayake. 2006. 'Constructing socio-economic status indices: how to use principal components analysis', *Health policy and planning*, 21: 459-68.
- Wagner, Glenn J, Mary Slaughter, and Bonnie Ghosh-Dastidar. 2017. 'Depression at treatment initiation predicts HIV antiretroviral adherence in Uganda', *Journal of the International Association of Providers of AIDS Care (JIAPAC)*, 16: 91-97.
- Waldron, Elizabeth M, Inger Burnett-Zeigler, Victoria Wee, Yiukee Warren Ng, Linda J Koenig, Aderonke Bamgbose Pederson, Evelyn Tomaszewski, and Emily S Miller. 2021. 'Mental health in women living with HIV: the unique and unmet needs', *Journal of the International Association of Providers of AIDS Care (JIAPAC)*, 20: 2325958220985665.